{"DataElement":{"publicId":"7801098","version":"1","preferredName":"Patient Current AJCC Melanoma Staging Clinical Trial Eligibility Criteria Code","preferredDefinition":"The code that represents the patient's current AJCC melanoma staging as outlined in the eligibility criteria of the protocol.","longName":"STAGING","context":"SWOG","contextVersion":"1","DataElementConcept":{"publicId":"7801093","version":"1","preferredName":"Patient Current American Joint Committee on Cancer Melanoma Staging Clinical Trial Eligibility Criteria","preferredDefinition":"A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary._Occurring in or belonging to the present time._A group formed for the purpose of developing a system of clinical staging for cancer that is acceptable to the American medical profession and is compatible with other accepted classifications._A malignant, usually aggressive tumor composed of atypical, neoplastic melanocytes. Most often, melanomas arise in the skin (cutaneous melanomas) and include the following histologic subtypes: superficial spreading melanoma, nodular melanoma, acral lentiginous melanoma, and lentigo maligna melanoma. Cutaneous melanomas may arise from acquired or congenital melanocytic or dysplastic nevi. Melanomas may also arise in other anatomic sites including the gastrointestinal system, eye, urinary tract, and reproductive system. Melanomas frequently metastasize to lymph nodes, liver, lungs, and brain._The process of defining at what point in the natural history of a malignant disease a patient is when a diagnosis is made._Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.","longName":"2233604v1.0:7802102v1.0","context":"SWOG","contextVersion":"1","ObjectClass":{"publicId":"2233604","version":"1","preferredName":"Patient","preferredDefinition":"A person who requires medical care.","longName":"C16960","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Patient","conceptCode":"C16960","definition":"A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F95D94B9-D847-2792-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-13","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-06-13","modifiedBy":"ONEDATA","dateModified":"2005-06-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"7802102","version":"1","preferredName":"Current American Joint Committee on Cancer Melanoma Staging Clinical Trial Eligibility Criteria","preferredDefinition":"Occurring in or belonging to the present time.:A group formed for the purpose of developing a system of clinical staging for cancer that is acceptable to the American medical profession and is compatible with other accepted classifications.:A malignant, usually aggressive tumor composed of atypical, neoplastic melanocytes. Most often, melanomas arise in the skin (cutaneous melanomas) and include the following histologic subtypes: superficial spreading melanoma, nodular melanoma, acral lentiginous melanoma, and lentigo maligna melanoma. Cutaneous melanomas may arise from acquired or congenital melanocytic or dysplastic nevi. Melanomas may also arise in other anatomic sites including the gastrointestinal system, eye, urinary tract, and reproductive system. Melanomas frequently metastasize to lymph nodes, liver, lungs, and brain.:Performing exams and tests to learn the extent of the cancer within the body, especially whether the disease has spread from the original site to other parts of the body. It is important to know the stage of the disease in order to plan the best treatment.:Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.","longName":"7802102v1.0","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Current","conceptCode":"C25471","definition":"Occurring in or belonging to the present time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"American Joint Committee on Cancer","conceptCode":"C39315","definition":"A group formed for the purpose of developing a system of clinical staging for cancer that is acceptable to the American medical profession and is compatible with other accepted classifications.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Melanoma","conceptCode":"C3224","definition":"A malignant, usually aggressive tumor composed of atypical, neoplastic melanocytes. Most often, melanomas arise in the skin (cutaneous melanomas) and include the following histologic subtypes: superficial spreading melanoma, nodular melanoma, acral lentiginous melanoma, and lentigo maligna melanoma. Cutaneous melanomas may arise from acquired or congenital melanocytic or dysplastic nevi. Melanomas may also arise in other anatomic sites including the gastrointestinal system, eye, urinary tract, and reproductive system. Melanomas frequently metastasize to lymph nodes, liver, lungs, and brain.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Staging","conceptCode":"C15608","definition":"The process of defining at what point in the natural history of a malignant disease a patient is when a diagnosis is made.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Clinical Trial Eligibility Criteria","conceptCode":"C16112","definition":"Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CFE4C6F7-CE37-64FB-E053-4EBD850A28CD","latestVersionIndicator":"Yes","beginDate":"2021-11-03","endDate":null,"createdBy":"TAYLORT","dateCreated":"2021-11-03","modifiedBy":"ONEDATA","dateModified":"2021-11-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008525","version":"1","preferredName":"Eligibility","preferredDefinition":"trial-specific criteria that a patient must meet to be enrolled.","longName":"ELIG","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1EC3968-9F25-305A-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-16","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-16","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CF5C6728-A9FE-4723-E053-4EBD850A8F85","latestVersionIndicator":"Yes","beginDate":"2021-10-27","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-10-27","modifiedBy":"TAYLORT","dateModified":"2021-12-09","changeDescription":"12/9/21 TL released AI. 10/27/21 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"7801095","version":"1","preferredName":"Melanoma Staging Code","preferredDefinition":"A malignant, usually aggressive tumor composed of atypical, neoplastic melanocytes. Most often, melanomas arise in the skin (cutaneous melanomas) and include the following histologic subtypes: superficial spreading melanoma, nodular melanoma, acral lentiginous melanoma, and lentigo maligna melanoma. Cutaneous melanomas may arise from acquired or congenital melanocytic or dysplastic nevi. Melanomas may also arise in other anatomic sites including the gastrointestinal system, eye, urinary tract, and reproductive system. Melanomas frequently metastasize to lymph nodes, liver, lungs, and brain._Performing exams and tests to learn the extent of the cancer within the body, especially whether the disease has spread from the original site to other parts of the body. It is important to know the stage of the disease in order to plan the best treatment.__A symbol or combination of symbols which is assigned to the members of a collection.","longName":"7801095v1.0","context":"SWOG","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":null,"minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"10","valueDescription":"Stage IIC - > 4.00mm with ulceration","ValueMeaning":{"publicId":"7801096","version":"1","preferredName":"Stage IIC - > 4.00mm with ulceration","longName":"7801096","preferredDefinition":"Stage IIC - > 4.00mm with ulceration","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CF5C6728-AA44-4723-E053-4EBD850A8F85","latestVersionIndicator":"Yes","beginDate":"2021-10-27","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-10-27","modifiedBy":"ONEDATA","dateModified":"2021-10-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"CF5C6728-AA5D-4723-E053-4EBD850A8F85","beginDate":"2021-10-27","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-10-27","modifiedBy":"ONEDATA","dateModified":"2021-10-27","deletedIndicator":"No"},{"value":"5","valueDescription":"Stage IIB - > 4.00mm without ulceration","ValueMeaning":{"publicId":"7801097","version":"1","preferredName":"Stage IIB - > 4.00mm without ulceration","longName":"7801097","preferredDefinition":"Stage IIB - > 4.00mm without ulceration","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CF5C6728-AA67-4723-E053-4EBD850A8F85","latestVersionIndicator":"Yes","beginDate":"2021-10-27","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-10-27","modifiedBy":"ONEDATA","dateModified":"2021-10-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"CF5C6728-AA80-4723-E053-4EBD850A8F85","beginDate":"2021-10-27","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-10-27","modifiedBy":"ONEDATA","dateModified":"2021-10-27","deletedIndicator":"No"},{"value":"4","valueDescription":"Stage IIB - 2.01-4.00mm with ulceration","ValueMeaning":{"publicId":"7800994","version":"1","preferredName":"Stage IIB - 2.01-4.00mm with ulceration","longName":"7800994","preferredDefinition":"Stage IIB - 2.01-4.00mm with ulceration","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CF574BD9-3574-5BD3-E053-4EBD850AF8B9","latestVersionIndicator":"Yes","beginDate":"2021-10-27","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-10-27","modifiedBy":"ONEDATA","dateModified":"2021-10-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"CF5C6728-AA94-4723-E053-4EBD850A8F85","beginDate":"2021-10-27","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-10-27","modifiedBy":"ONEDATA","dateModified":"2021-10-27","deletedIndicator":"No"},{"value":"12","valueDescription":"Stage IIA - 2.01-4.00mm without ulceration","ValueMeaning":{"publicId":"7800995","version":"1","preferredName":"Stage IIA - 2.01-4.00mm without ulceration","longName":"7800995","preferredDefinition":"Stage IIA - 2.01-4.00mm without ulceration","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CF574BD9-3597-5BD3-E053-4EBD850AF8B9","latestVersionIndicator":"Yes","beginDate":"2021-10-27","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-10-27","modifiedBy":"ONEDATA","dateModified":"2021-10-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"CF5C6728-AAA9-4723-E053-4EBD850A8F85","beginDate":"2021-10-27","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-10-27","modifiedBy":"ONEDATA","dateModified":"2021-10-27","deletedIndicator":"No"},{"value":"11","valueDescription":"Stage IIA - 1.01-2.00mm with ulceration","ValueMeaning":{"publicId":"7800996","version":"1","preferredName":"Stage IIA - 1.01-2.00mm with ulceration","longName":"7800996","preferredDefinition":"Stage IIA - 1.01-2.00mm with ulceration","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CF574BD9-35BA-5BD3-E053-4EBD850AF8B9","latestVersionIndicator":"Yes","beginDate":"2021-10-27","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-10-27","modifiedBy":"ONEDATA","dateModified":"2021-10-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"CF5C6728-AABE-4723-E053-4EBD850A8F85","beginDate":"2021-10-27","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-10-27","modifiedBy":"ONEDATA","dateModified":"2021-10-27","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008525","version":"1","preferredName":"Eligibility","preferredDefinition":"trial-specific criteria that a patient must meet to be enrolled.","longName":"ELIG","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1EC3968-9F25-305A-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-16","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-16","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"7801100","version":"1","preferredName":"Melanoma Staging Code","preferredDefinition":"A malignant, usually aggressive tumor composed of atypical, neoplastic melanocytes. Most often, melanomas arise in the skin (cutaneous melanomas) and include the following histologic subtypes: superficial spreading melanoma, nodular melanoma, acral lentiginous melanoma, and lentigo maligna melanoma. Cutaneous melanomas may arise from acquired or congenital melanocytic or dysplastic nevi. Melanomas may also arise in other anatomic sites including the gastrointestinal system, eye, urinary tract, and reproductive system. Melanomas frequently metastasize to lymph nodes, liver, lungs, and brain.:Performing exams and tests to learn the extent of the cancer within the body, especially whether the disease has spread from the original site to other parts of the body. It is important to know the stage of the disease in order to plan the best treatment.:A symbol or combination of symbols which is assigned to the members of a collection.","longName":"C3224:C15608:C25162","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Melanoma","conceptCode":"C3224","definition":"A malignant, usually aggressive tumor composed of atypical, neoplastic melanocytes. Most often, melanomas arise in the skin (cutaneous melanomas) and include the following histologic subtypes: superficial spreading melanoma, nodular melanoma, acral lentiginous melanoma, and lentigo maligna melanoma. Cutaneous melanomas may arise from acquired or congenital melanocytic or dysplastic nevi. Melanomas may also arise in other anatomic sites including the gastrointestinal system, eye, urinary tract, and reproductive system. Melanomas frequently metastasize to lymph nodes, liver, lungs, and brain.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Staging","conceptCode":"C15608","definition":"The process of defining at what point in the natural history of a malignant disease a patient is when a diagnosis is made.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Code","conceptCode":"C25162","definition":"A symbol or combination of symbols which is assigned to the members of a collection.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CF5A5267-1B88-0314-E053-4EBD850A606F","latestVersionIndicator":"Yes","beginDate":"2021-10-27","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-10-27","modifiedBy":"ONEDATA","dateModified":"2021-10-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CF5C6728-AA2E-4723-E053-4EBD850A8F85","latestVersionIndicator":"Yes","beginDate":"2021-10-27","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-10-27","modifiedBy":"TAYLORT","dateModified":"2021-12-09","changeDescription":"12/9/21 TL released AI. 10/27/21 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"Current AJCC Melanoma Staging","type":"Preferred Question Text","description":"Current AJCC Melanoma Staging","url":null,"context":"SWOG"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CF5C6728-AACB-4723-E053-4EBD850A8F85","latestVersionIndicator":"Yes","beginDate":"2021-10-27","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-10-27","modifiedBy":"TAYLORT","dateModified":"2021-12-09","changeDescription":"12/9/21 TL released AI. S2015 Enrollment Question.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}